螯合疗法
地中海贫血
脱铁酮
去铁斯若
医学
螯合作用
β地中海贫血
不利影响
去铁胺
重症监护医学
内科学
化学
有机化学
标识
DOI:10.1016/j.hoc.2022.12.013
摘要
Conventional therapy for severe thalassemia includes regular red cell transfusions and iron chelation therapy to prevent and treat complications of iron overload . Iron chelation is very effective when appropriately used, but inadequate iron chelation therapy continues to contribute to preventable morbidity and mortality in transfusion-dependent thalassemia. Factors that contribute to suboptimal iron chelation include poor adherence, variable pharmacokinetics , chelator adverse effects, and difficulties with precise monitoring of response. The regular assessment of adherence, adverse effects, and iron burden with appropriate treatment adjustments is necessary to optimize patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI